Immunic AG – Home

Immunic is the specialist for selective oral drugs in immunology. As a clinical stage company, we deliver clinical proof-of-concept for best-in-class therapies of Th1 and Th17 mediated chronic inflammatory diseases.


Immunic AG is based in the Munich biotech hub Martinsried and currently develops two products for the treatment of chronic inflammatory diseases including e.g. IBD and psoriasis. IMU-838 will be tested in a phase IIb trial in patients suffering from ulcerative colitis beginning of 2018. IMU-366 is a best-in-class inverse agonist of the nuclear receptor ROR gamma-t and currently in advanced preclinical stage.

Immunic Therapeutics Successfully Completes two Phase 1 Studies for IMU-838

Two phase 1 studies for IMU-838 in healthy volunteers have been completed Compound was safe and well tolerated at all doses tested New dosing regimen was determined allowing safe administration ...
Read More

Immunic will attend Bio-Europe, which will take place November 6-8, 2017 in Berlin, Germany.

The 23rd annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. This year over 3,800 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe. It ...
Read More

Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million

  Omega and Fund+ broaden Immunic’s investor base and add an additional EUR 10 million (USD 12 million) in equity financing Series A financing round now completed with an overall ...
Read More